A PILOT STUDY ON QUASSIA AMARA LINN.: A NEWLY EMERGING DRUG FOR TYPE 2 DIABETES

Ankush Gunjal 1, Mandip Goyal 2, Jitendra Varsakiya 3*

1 Assistant Professor, Department of Kayachikitsa, SMBT Ayurveda College and Hospital, Nasik, Maharashtra, India
2 Associate Professor, Department of Kayachikitsa, IPGT & RA, Gujarat Ayurved University, Jamnagar, India
3 Assistant Professor, Department of Kayachikitsa, J.S Ayurveda Mahavidhyalaya, Nadiad, Gujarat, India

Received on: 12/08/17 Accepted on: 20/09/17

*Corresponding author
E-mail: jeet12989@gmail.com

DOI: 10.7897/2277-4343.085242

ABSTRACT

Though the awareness about Health in community is raising, changes in dietary habits and lifestyle of people from all age groups has resulted emergence of various non communicable diseases. Among these non communicable diseases diabetes tops the list and has overtaken communicable diseases with respect to overall mortality, even in developing countries like India. *Quassia amara* Linn. an ethno medicinal plant finds no direct reference in Ayurvedic classics, Quassin constituent of *Quassia amra* in it is one of the bitterest substances found in nature. The bitters plants are generally showing anti-diabetic and tonic action. For this clinical study, 58 cases of recently diagnosed, mild to moderate cases of type 2 diabetes were administered capsules filled with heartwood powder of *Quassia amara* Linn., 3 capsules (500mg each) twice daily before food with lukewarm water along with controlled diet for 60 days. To assess the effect of trial drug fasting Blood sugar, post parandial blood sugar, lipid profile and BMI were done before and after the completion of 60 days of the treatment. It was observed that treatment with cap. *Quassia amara* provided statistically highly significant reduction of 19.33% in fasting blood sugar level and of 22.05% in Post Prandial Blood Sugar levels. Similarly, significant decrease of 9.95% in serum Cholesterol level and that of 13.63 % in S. Triglyceride level and 1.52% decrease in BMI was found. It showed the potential of *Quassia amara* Linn. heartwood powder as single herb therapy in patients of type 2 diabetes.

Keywords: *Quassia amara* Linn. Type 2 Diabetes. Anti diabetic effect

INTRODUCTION

High prevalence rates of diabetes are seen not only in affluent migrant Indians, but also in those living within the subcontinent. Indeed, the epidemic of diabetes is now spreading to the middle and lower income groups in India1. The disease currently affects more than 62 million Indians, which is more than 7.1% of India's adult population2. Globally, as of 2010, an estimated 285 million people had diabetes, with type 2 making up about 90% of the cases3. Fatty diets and decreased physical activity have accompanied the benefits of modernization. Exercise has been engineered out of our daily lives, both in the work place & leisure. These lifestyle changes and effects of pre-existing genes are cause of type 2 diabetes epidemic that the world is witnessing today.

The description of *Quassia amara* is available in ‘The Wealth of India’ (CSIR). It is available wildly in abundance and readily available source of medicine. *Quassia amara* Linn. being an ethnomedicinal plant assumes importance and no clinical data in patients of type 2 diabetes was available on this plant. Quassin constituent in it is one of the bitterest substances found in nature and it has been used in management of type 2 diabetes.

The anti diabetic activity studies were carried out in diabetic rats treated with oral doses of 100 and 200mg/kg of *Quassia amara* Linn. extract. Both doses of *Quassia amara* Linn. extract significantly reduced elevated fasting blood glucose levels in diabetic rats, significantly increased the glucose tolerance compared with the vehicle and effectively normalized dyslipidemia associated with streptozotocin-induced diabetes4. The anti-hyperglycemic effect of wood powder of *Quassia amara* Linn. was evaluated in normal and in alloxan diabetes-induced rats and it showed anti-hyperglycemic effects, similar to metformin in the diabetic animals when compared to the control group5. A desirable anti-diabetic agent is that which would not lower the blood glucose level below the normal level in normoglycaemics and should have a good blood glucose lowering effect in hyperglycaemic subjects

Aims & objectives

To evaluate of anti-diabetic effect of heartwood ‘*Quassia amara* Linn.’ in the patients of type 2 diabetes.

MATERIALS AND METHODS

For this clinical study, patients fulfilling the diagnostic criteria of the study were selected from O.P.D. and IPD of Kayachikitsa department, I.P.G.T & R.A, Gujarat Ayurved University, Jamnagar during the period of February 2014 to June 2015. Institutional ethics committee approval was taken prior to initiation of research vide letter No. PGT/7-8/Ethics/2013-14/2753 Dated 9-12-2013. Study was registered in CTRI with no. CTRI/2014/07/004775 dated 25/7/2014. The market sample of heartwood of herb *Quassia amara* Linn. was procured from Mumbai. The pharmacognostical authentication and pharmacognostical analysis of *Quassia amara* Linn. was done on the basis of morphological features, organoleptic characters and powder microscopy of the sample drug and was performed at pharmacognostical and pharmaceutical laboratory of IPGT and RA, G.A.U, Jamnagar.

Criteria for Diagnosis

Standard criteria of National Diabetes Data Group and the World Health Organization (W.H.O.) for Diabetes Mellitus were
adopted which was presence of symptoms of diabetes Mellitus like polyuria, polyphagia, polydypsia, etc. Random blood glucose concentration ≥ 11.1 mm d/L (200 mg/dL) or Fasting blood glucose ≥ 7.0mm d/L (126mg/dL) or Two hours blood glucose ≥ 11.1 mm d/L (200 mg/dL) (Adopted by American Diabetic Association).

Inclusion Criteria

- Age between 40 years to 70 years.
- Known patient of Type 2 diabetes and also the patients preliminarily diagnosed Type 2 diabetes on the basis of signs and symptoms of the disease were confirmed by FBS and PPBS.

Exclusion Criteria

- Age below 40 years & above 70 years.
- Patients of Type I diabetes.
- Patients suffering from: Malignant and accelerated hypertension, CVS disorder (CAD), Pregnant woman and planning to be pregnant within six months, Lactating mother, Secondary diabetes mellitus, diabetic ketosis, CNS illness and also patients suffering from tuberculosis, carcinoma endocrine disorders like, Thyrotoxicosis, Cushing Syndrome etc. and HIV positive patients.

Investigations

For the purpose of assessing the general condition of the patient and to exclude other pathologies investigations like complete haemogram, Blood urea, serum creatinine, SGPT, SGOT and ESR were carried out before intervention of treatment. To assess the effect of trial drug fasting blood sugar, post prandial blood sugar, lipid profile, Urine examination for routine and microscopic aspects were carried out before and after the completion of 60 days of the treatment.

Posology

The 58 patients were recently diagnosed patients, mild to moderate cases of type 2 diabetes were administered Quassia amara capsules (capsules filled with heartwood powder of Quassia amara Linn.) in the dose of 3 capsules (500mg each) (3 gm/day) along with Luke warm water orally twice a day before meals for the duration of 6 days along with controlled diet. For the present study, total 58 patients of type 2 diabetes were registered, out of which 55 patients completed full course of treatment. The data of 55 patients who completed the management course was analysed by statistical methods. Paired t -test was performed by using SigmaStat® 3.1 software. The obtained results were interpreted as > 0.05 was considered as insignificant, ≤ 0.05 as significant and ≤ 0.01 as highly significant.

RESULTS AND DISCUSSION

Data on analysis revealed that trial drug provided highly significant reduction of 19.33% in fasting blood sugar level. On further analyzing the data it was found that fasting blood sugar level was significantly reduced by 20.02% in those patients, who were suffering from type 2 diabetes from 1-9 yrs. In patients of type 2 diabetes having chronicity of 5-10 years significant reduction (p≤0.05) of 18.25% in fasting blood sugar level was observed. The analysis of data depicts highly significant reduction of 22.05% in post prandial blood sugar levels in the patients. Further details of the data revealed that in patients of type 2 diabetes who were having having chronicity of 1-4 years, highly significant reduction of 24.46% in post prandial Blood Sugar levels was observed. Similarly, highly significant reduction of 18.05% in post prandial blood sugar level was observed in the patients. The data related to Serum Cholesterol on statistical analysis depicts highly significant decrease of 9.95% and that of 13.63% in Serum Triglyceride. (Table 1)

The test drug provided highly significant decrease of 20.64% in the patients who were having Kapha-Pitta Prakruti. Similarly, highly significant decrease of 26.68% was observed in patients of the diabetes who were having Pitta-Kapha Prakruti, However the parameters in the patients having Pitta-Vata Prakruti was insignificant. Significant decrease of 21.63% and 28.49% was provided by test drug in Post Prandial Blood Sugar level of patients of who having Kapha-Pitta Prakruti and Pitta-Kapha Prakruti, However, The test drug provided insignificant decrease of 14.92% in patients who having Pitta-Vata Prakruti. (Table 2)

Analysis of overall effect of the Quassia amara Linn. showed that treatment with this drug provided excellent response in 12.72% of the patients, marked response in 45.45 % of the patients, moderate response in 27.27% and mild response in 14.54% of the patients.

In recent years, ethno-medicinal research works are being widely carried out in order to document indigenous knowledge on the use of plants and for providing an inventory of useful plants from local flora. Quassia amara Linn. being an ethnomedicinal plant assumes importance as there is no planned study available on this plant. The plant finds no direct reference in Ayurvedic classics, although it is stated in Aadarasha Nighantu that Indian quassia (Picrasma quassioides) is having equal medicinal properties as that of Quassia amara Linn. Modern botanical texts, various medicas and glossaries explain the plant with its taxonomical description.

In diabetic state there is beta cell failure leading to reduced basal insulin secretion in fasting state, trial drug has shown fasting blood sugar lowering effect which is statistically significant. It shows possibility of beta cell protective or regenerative effect of Quassia amara Linn. The drug is fibrous and the possible mechanisms for metabolic improvements with dietary fibre include delay of glucose absorption, increase in hepatic extraction of insulin, increased insulin sensitivity at the cellular level, and binding of bile acids. Research studies reported that beta-sitosterol (constituent in Quassia amara Linn.) decreases the fasting hyperglycemia when was administered and increased the fasting plasma insulin levels.
In the present study, PPBS level was reduced significantly; this may be because of increased beta cell response to the oral glucose uptake, retarding the carbohydrate absorption from intestine and improvement in peripheral glucose uptake. Pancreatic α-amylase inhibitors offer an effective strategy to lower the levels of post prandial hyperglycemia via control of starch breakdown. Phytochemical analysis revealed the presence of tannins, cardiac glycosides, flavonoids and steroids as probable Pancreatic α-amylase inhibitory compounds of *Quassia amara* Linn.  

### CONCLUSION

In the present scenario, Ayurved herbs have become more popular for the management of the chronic, progressive diseases like type 2 diabetes. From the findings of present clinical trial *Quassia* had proved to have anti-diabetic, anti-hyperlipidemic and anti hyperglycemic effect in the case of type 2 diabetes. Further large sample size study may help to establish *Quassia amara* Linn. as choice of drug for the treatment of type 2 diabetes.

### REFERENCES

6. Ferreira S.F; Azevedo S.C.S.F; Vardaneiga-Perieh M; Pagadigorgia C.L.S; Garcia R.F, Anti-hyperglycemic effect

### Table 1: Effect of test drug *Quassia amara* on Fasting Blood Sugar level in the patients of Type 2 diabetes

<table>
<thead>
<tr>
<th>Parameters</th>
<th>N</th>
<th>Mean Score</th>
<th>Mean %</th>
<th>Paired ‘t’ test</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS</td>
<td>(n=55)</td>
<td>211.23</td>
<td>169.4</td>
<td>41.83</td>
</tr>
<tr>
<td>FBS level (chronicity 1-4 years)</td>
<td>(n=34)</td>
<td>209.23</td>
<td>167.38</td>
<td>41.85</td>
</tr>
<tr>
<td>FBS level (chronicity 5-10 years)</td>
<td>(n=20)</td>
<td>215</td>
<td>176</td>
<td>39.25</td>
</tr>
<tr>
<td>PPBS level (mg/dl)</td>
<td>(n=55)</td>
<td>303.98</td>
<td>236.30</td>
<td>67.67</td>
</tr>
<tr>
<td>PPBS level (mg/dl) (chronicity 1-4 years)</td>
<td>(n=34)</td>
<td>303.08</td>
<td>228.94</td>
<td>74.14</td>
</tr>
<tr>
<td>Serum Triglyceride</td>
<td>(n=55)</td>
<td>185.02</td>
<td>166.69</td>
<td>18.32</td>
</tr>
<tr>
<td>Serum HDL</td>
<td>(n=54)</td>
<td>48.02</td>
<td>45.40</td>
<td>2.62</td>
</tr>
<tr>
<td>SGPT</td>
<td>(n=55)</td>
<td>20.77</td>
<td>25.34</td>
<td>1.52</td>
</tr>
<tr>
<td>SGOT</td>
<td>(n=54)</td>
<td>28.79</td>
<td>31.21</td>
<td>2.83</td>
</tr>
<tr>
<td>S.Creatinine</td>
<td>(n=55)</td>
<td>20.77</td>
<td>23.24</td>
<td>1.52</td>
</tr>
</tbody>
</table>

BT: Before Treatment, AT: After Treatment,

HS=Highly significant, S= Significant, ↓= Decrease, Sig= significance,

FBS: Fasting Blood Sugar, PPBS: Post Prandial Blood Sugar

### Table 2: Classification according to *Dosha* wise

<table>
<thead>
<tr>
<th>Parameters</th>
<th>N</th>
<th>Mean Score</th>
<th>Mean %</th>
<th>Paired ‘t’ test</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS level of patients having Kapha-Pitta Prakriti</td>
<td>(n=19)</td>
<td>214.89</td>
<td>170.52</td>
<td>44.36</td>
</tr>
<tr>
<td>FBS level of patients having Pitta-Kapha Prakriti</td>
<td>(n=17)</td>
<td>234.29</td>
<td>171.76</td>
<td>62.52</td>
</tr>
<tr>
<td>FBS level (mg/dl)</td>
<td>(Pitta-Vata Prakriti)</td>
<td>(n=10)</td>
<td>180.70</td>
<td>164.90</td>
</tr>
<tr>
<td>PPBS level (mg/dl) (Kapha-Pitta Prakriti)</td>
<td>(n=19)</td>
<td>310.68</td>
<td>243.47</td>
<td>67.21</td>
</tr>
<tr>
<td>PPBS level (mg/dl) (Pitta-Kapha Prakriti)</td>
<td>(n=17)</td>
<td>316.05</td>
<td>226.00</td>
<td>90.05</td>
</tr>
<tr>
<td>PPBS level (mg/dl) (Pitta-Vata Prakriti)</td>
<td>(n=10)</td>
<td>273.40</td>
<td>232.60</td>
<td>40.80</td>
</tr>
</tbody>
</table>

BT: Before Treatment, AT: After Treatment,

HS=Highly significant, S= Significant, ↓= Decrease, Sig= significance,

FBS: Fasting Blood Sugar, PPBS: Post Prandial Blood Sugar

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IJRAP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJRAP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IJRAP editor or editorial board members.